Related Research Articles
Monash University is a public research university based in Melbourne, Victoria, Australia. Named after prominent World War I general Sir John Monash, it was founded in 1958 and is the second oldest university in the state. The university has a number of campuses, four of which are in Victoria, and one in Malaysia. Monash also has a research and teaching centre in Prato, Italy, a graduate research school in Mumbai, India and graduate schools in Suzhou, China and Tangerang, Indonesia. Monash University courses are also delivered at other locations, including South Africa.
Pharmacy is the science and practice of discovering, producing, preparing, dispensing, reviewing and monitoring medications, aiming to ensure the safe, effective, and affordable use of medicines. It is a miscellaneous science as it links health sciences with pharmaceutical sciences and natural sciences. The professional practice is becoming more clinically oriented as most of the drugs are now manufactured by pharmaceutical industries. Based on the setting, pharmacy practice is either classified as community or institutional pharmacy. Providing direct patient care in the community of institutional pharmacies is considered clinical pharmacy.
Monash University, Parkville campus is a campus of Monash University, located in Parkville, Victoria, Australia. It is home to the Faculty of Pharmacy and Pharmaceutical Sciences. Founded in 1881 and previously known as the Victorian College of Pharmacy, the faculty is the oldest school of pharmacy in Australia. A major centre of research and teaching, it is internationally regarded for its research in drug target biology and discovery, medicinal chemistry, drug development, formulation science, and medicine use and safety, including the discovery and development of the world's first successful anti-influenza drug, Relenza. In international rankings, it is ranked as the number one school of pharmacy and pharmacology in Australia and worldwide.
Anders Hallberg is a Swedish pharmaceutical researcher, professor in medicinal chemistry and 2006-2011 Rector Magnificus and Vice Chancellor at Uppsala University.
Robert R. Ruffolo was president of research and development for Wyeth Pharmaceuticals, and corporate senior vice president of Wyeth from 2001 to 2008. In that role, he managed an R&D organization of 7,000 scientists, with an annual budget of $3 billion. During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension. He holds the patent for the discovery of use of carvedilol (Coreg) for the treatment of congestive heart failure which changed the paradigm for the treatment of this devastating disease, and he led the research team that discovered ropinerole (Requip) for Parkinson's Disease. Ruffolo was awarded the Discoverers Award in 2008 by the Pharmaceutical Research and Manufacturers Association (PhRMA), for his pioneering work on the discovery of carvedilol for congestive heart failure.
Alan Simon Finkel is an Australian neuroscientist, inventor, researcher, entrepreneur, educator, policy advisor, and philanthropist. He was Australia’s Chief Scientist from 2016 to 2020. Prior to his appointment, his career included Chancellor of Monash University, President of the Australian Academy of Technology and Engineering (ATSE), and CEO and founder of Axon Instruments, and CTO for the electric car start-up Better Place Australia.
Arie Freiberg is an Israeli-born Australian legal academic. He was formerly Dean of Monash Law School from 2004 and retired at the end of 2012. His expertise is in criminal law and criminology and he is current Chair of the Victorian Sentencing Advisory Council. His research has focussed on sentencing and the administration of criminal justice, but he has over one hundred publications in many areas of law.
Sir Brian Mellor Greenwood, CBE, FRCP, FRS is a British physician, biomedical research scientist, academic, and recipient of the first Hideyo Noguchi Africa Prize.
Nicholas (Nikolaos) A. Peppas is a chemical and biomedical engineer whose leadership in biomaterials science and engineering, drug delivery, bionanotechnology, pharmaceutical sciences, chemical and polymer engineering has provided seminal foundations based on the physics and mathematical theories of nanoscale, macromolecular processes and drug/protein transport and has led to numerous biomedical products or devices.
Dr. William E. Evans, Pharm.D. served as St. Jude Children’s Research Hospital’s fifth director and CEO from 2004 to 2014. From 1986 to 2002, he chaired the St. Jude Department of Pharmaceutical Sciences, and from 2002 to 2004 served as the hospital’s scientific director and executive vice president. He also currently holds the St. Jude Professorship and Endowed chair at the University of Tennessee College of Medicine and Pharmacy.
Krisana Kraisintu is a Thai professor and pharmacist, as known as the "Gypsy pharmacist". She was pharmaceutical consultant in the local production and increased access to life-saving medicines in Africa, in particular, malaria and HIV/AIDS-related drug production.
Michael Cowley FTSE is an Australian physiologist. He is best known for his mapping of the neural circuits involved in metabolism and obesity and diabetes treatment. He is a professor in the Department of Physiology at Monash University in the Faculty of Biomedical and Psychological Sciences. He is also a director of the Australian diabetes drug development company, Verva Inc, and director of the Monash Obesity & Diabetes Institute] (modi).
Vladimir Petrovich Torchilin is a Soviet, Russian and American biochemist, pharmacologist, and an expert in medical nanotechnology. Torchillin is a University Distinguished Professor of Pharmaceutical Sciences at Northeastern University. He also serves as a director at both the Center for Translational Cancer Nanomedicine and at the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University.
Trevor Mervyn Jones, CBE PhD DSc (Hon) FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.
Kenneth John Harvey AM is an Australian public health doctor, currently Honorary Adjunct Associate Professor at the Institute for Evidence-Based Healthcare in Bond University. Described by The Age as an "anti-quackery crusader", Harvey is an advocate of evidence-based medicine and a critic of pharmaceutical marketing and unproven diet products. He is the president of Friends of Science in Medicine. In 2017, Harvey was awarded a Member of the Order of Australia (AM) for his "significant service to community health and the pharmaceutical industry”.
Chinedum Peace BabalolaFAS, FAAS is a Nigerian Professor of Pharmaceutical chemistry and Pharmacokinetics. She is the first female Professor of Pharmacy in the University of Ibadan, FAS and FAAS and the second female Nigerian FAAS. She is the incumbent Vice Chancellor of Chrisland University, Nigeria.
Harkishan Singh was Professor Emeritus at the Panjab University. He was a well recognized pharmaceutical academic, medicinal chemistry researcher and science historian. He had more than half a century experience in his respective fields to his credit. He worked at the Banaras Hindu University, University of Saugar, and the Panjab University in India, and abroad at the University of Maryland, University of Mississippi and the University of London.
Liu Xu was a Chinese pharmaceutical chemist known for the discovery of artesunate, a novel antimalarial drug. The discovery of artesunate solves the problem that artemisinin is nearly insoluble in water. Artesunate can be given by intravenous injection, intramuscular injection, by mouth, and by rectum.
Jonathan Baell is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco. Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS), the director of the Australian Translational Medicinal Chemistry Facility and a Chief Investigator at the ARC Centre for Fragment-Based Design. He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board. His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases.
Halidou Tinto is a Professor of parasitology and global health scientist with research that has contributed to understanding and combating malaria in Sub-Saharan Africa. Tinto founded the Clinical Research Unit of Nanaro (CRUN) in Burkina Faso as part of the Institut de Recherche en Sciences de la Santé (IRSS). Tinto is now the Regional Director of the IRSS, and throughout his career he has contributed to the study of antimalarial drug resistance and the development of malaria vaccines.
References
- ↑ Monash Newsline (Monash University) Archived 19 August 2008 at the Wayback Machine
- ↑ Dean receives prestigious international recognition - (Monash Memo, 23 May 2007) Archived 5 March 2011 at the Wayback Machine
- ↑ Monash University - Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, Professor Bill Charman is stepping down
- ↑ "William N. Charman, Ph.D." unceii.org.
- ↑ 125 stories for 125 years Archived 21 July 2008 at the Wayback Machine
- ↑ Radio Australia - Innovations - ‘Oz’ Kills Malaria Parasite Archived 21 May 2008 at the Wayback Machine